MA39145B1 - Dérivés de pipérazine ayant une activité multimode contre la douleur - Google Patents

Dérivés de pipérazine ayant une activité multimode contre la douleur

Info

Publication number
MA39145B1
MA39145B1 MA39145A MA39145A MA39145B1 MA 39145 B1 MA39145 B1 MA 39145B1 MA 39145 A MA39145 A MA 39145A MA 39145 A MA39145 A MA 39145A MA 39145 B1 MA39145 B1 MA 39145B1
Authority
MA
Morocco
Prior art keywords
multimode
activity against
piperazine derivatives
against pain
compounds
Prior art date
Application number
MA39145A
Other languages
English (en)
Other versions
MA39145A1 (fr
Inventor
Carmen Almansa-Rosales
Cordobes Felix Cuevas
Lopez Monica Garcia
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA39145A1 publication Critical patent/MA39145A1/fr
Publication of MA39145B1 publication Critical patent/MA39145B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés présentant une activité pharmacologique double envers à la fois le récepteur sigma (s), et le récepteur µ-opioïde, et plus particulièrement des composés de pipérazine qui ont cette activité pharmacologique, des procédés de préparation de tels composés, des compositions pharmaceutiques les comprenant, et leur utilisation en thérapie, en particulier pour le traitement de la douleur.
MA39145A 2013-12-20 2014-12-19 Dérivés de pipérazine ayant une activité multimode contre la douleur MA39145B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13384006 2013-12-20
PCT/EP2014/078852 WO2015092009A1 (fr) 2013-12-20 2014-12-19 Dérivés de pipérazine ayant une activité multimode contre la douleur

Publications (2)

Publication Number Publication Date
MA39145A1 MA39145A1 (fr) 2017-10-31
MA39145B1 true MA39145B1 (fr) 2018-05-31

Family

ID=49998042

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39145A MA39145B1 (fr) 2013-12-20 2014-12-19 Dérivés de pipérazine ayant une activité multimode contre la douleur

Country Status (17)

Country Link
US (2) US10351535B2 (fr)
EP (1) EP3083563A1 (fr)
JP (1) JP6553615B2 (fr)
KR (1) KR20160098506A (fr)
CN (1) CN105829287B (fr)
AU (1) AU2014368368C1 (fr)
CA (1) CA2932051A1 (fr)
IL (1) IL245808B (fr)
MA (1) MA39145B1 (fr)
MX (1) MX2016008130A (fr)
MY (1) MY179509A (fr)
PH (1) PH12016500978A1 (fr)
RU (1) RU2709482C1 (fr)
SG (1) SG10201805267UA (fr)
TN (1) TN2016000203A1 (fr)
UA (1) UA120754C2 (fr)
WO (1) WO2015092009A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018525363A (ja) * 2015-07-29 2018-09-06 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有する置換アミド誘導体
ES2760625T3 (es) * 2015-07-29 2020-05-14 Esteve Pharmaceuticals Sa Derivados de N-(2-(3-(bencil(metil)amino)pirrolidin-1-il)etil)-N-fenil)propionamida y compuestos relacionados como ligandos duales de receptores sigma 1 y opioide mu y para el tratamiento del dolor
TW201808937A (zh) 2016-05-20 2018-03-16 艾斯提夫博士實驗股份有限公司 針對疼痛具有多模態活性的四氫哌喃和噻喃衍生物
MA49019A (fr) 2017-03-21 2020-02-05 Univ Temple Nouveaux modulateurs du récepteur sigma 2 et leur procédé d'utilisation
US11220505B2 (en) 2017-03-21 2022-01-11 Temple University-Of The Commonwealth System Of Higher Education 5-hydroxytryptamine receptor 7 modulators and their use as therapeutic agents
HRP20220331T1 (hr) 2018-03-08 2022-05-13 Incyte Corporation Spojevi aminopirazin diola kao inhibitori pi3k-y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
EP3753932A1 (fr) * 2019-06-17 2020-12-23 Esteve Pharmaceuticals, S.A. Dérivés bicycliques substitués ayant une activité pluri-modale contre la douleur
WO2022187206A1 (fr) * 2021-03-01 2022-09-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ligands à double cible des récepteurs des opiacés mu et dopaminergiques d3 ; préparation et utilisation correspondants
WO2024105225A1 (fr) 2022-11-18 2024-05-23 Universitat De Barcelona Combinaisons synergiques d'un antagoniste du récepteur sigma 1 (s1r) et d'un inhibiteur d'époxyde hydrolase soluble (sehi) et leur utilisation dans le traitement de la douleur

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2580648B1 (fr) * 1985-04-17 1987-05-15 Adir Nouveaux derives du triazole, leur procede de preparation et les compositions pharmaceutiques les renfermant
ZA871335B (en) * 1986-02-27 1987-09-30 Duphar Int Res New aryl-substituted(n-piperidinyl)methyl-and(n-piperazinyl)-methylazoles having antipsychotic properties
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
EP2009005A4 (fr) * 2006-04-19 2010-06-02 Astellas Pharma Inc Dérivé d'azolecarboxamide
WO2008008480A2 (fr) * 2006-07-12 2008-01-17 Cumbre Pharmaceuticals Inc. Dérivés de rifamycine contenant du nitrohétéroaryl
TW200817375A (en) * 2006-07-21 2008-04-16 Irm Llc Compounds and compositions as ITPKB inhibitors
EP2078003B1 (fr) * 2006-10-31 2017-03-08 Merck Sharp & Dohme Corp. Dérivés d'anilinopipérazine et leurs méthodes d'utilisation
MX2009006517A (es) * 2006-12-27 2009-06-26 Sanofi Aventis Nuevos derivados de isoquinolina e isoquinolinona sustituidos.
EP1982714A1 (fr) * 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-aminés
CA2683461A1 (fr) 2007-04-16 2008-10-23 Gruenenthal Gmbh Nouveaux ligands du recepteur vanilloide et leur utilisation pour la fabrication de medicaments
PL2155717T3 (pl) * 2007-05-11 2013-03-29 Lilly Co Eli 2-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-3-FENYLO PIRAZYNY I PIRYDYNY I 3-[4-(PIRAZOL-4-ILOALKILO)PIPERAZYN-1-YLO]-2-FENYLO PIRYDYNY JAKO ANTAGONIŚĆI RECEPTORA 5-HT<sub>7</sub>
WO2008157844A1 (fr) 2007-06-21 2008-12-24 Forest Laboratories Holdings Limited Nouveaux dérivés de pipérazine en tant qu'inhibiteurs de stéaroyl-coa désaturase
TW200914020A (en) 2007-08-28 2009-04-01 Lilly Co Eli Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists
EP3101018B1 (fr) 2007-08-31 2019-03-06 Purdue Pharma L.P. Composés de pipéridine de type quinoxaline substituée et leurs utilisations
WO2010046780A2 (fr) 2008-10-22 2010-04-29 Institut Pasteur Korea Composés antiviraux
CN102271681B (zh) * 2008-11-04 2014-11-12 凯莫森特里克斯股份有限公司 Cxcr7调节剂
US8853202B2 (en) * 2008-11-04 2014-10-07 Chemocentryx, Inc. Modulators of CXCR7
US8809538B2 (en) 2009-01-12 2014-08-19 Array Biopharma Inc. Piperidine-containing compounds and use thereof
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
EP2395003A1 (fr) * 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Composés pyrazoliques en tant qu'inhibiteurs du récepteur sigma
WO2011150183A1 (fr) * 2010-05-28 2011-12-01 Ge Healthcare Limited Composés radiomarqués et leurs procédés

Also Published As

Publication number Publication date
CA2932051A1 (fr) 2015-06-25
RU2709482C1 (ru) 2019-12-18
UA120754C2 (uk) 2020-02-10
US10351535B2 (en) 2019-07-16
MY179509A (en) 2020-11-09
KR20160098506A (ko) 2016-08-18
IL245808B (en) 2020-03-31
US20170001967A1 (en) 2017-01-05
AU2014368368C1 (en) 2019-06-27
CN105829287B (zh) 2019-08-27
JP6553615B2 (ja) 2019-07-31
US10745361B2 (en) 2020-08-18
AU2014368368B2 (en) 2019-01-31
MA39145A1 (fr) 2017-10-31
MX2016008130A (es) 2016-10-13
PH12016500978A1 (en) 2016-06-20
RU2016129110A (ru) 2018-01-23
WO2015092009A1 (fr) 2015-06-25
EP3083563A1 (fr) 2016-10-26
CN105829287A (zh) 2016-08-03
JP2016540792A (ja) 2016-12-28
AU2014368368A1 (en) 2016-07-07
SG10201805267UA (en) 2018-07-30
US20190276415A1 (en) 2019-09-12
IL245808A0 (en) 2016-08-02
TN2016000203A1 (en) 2017-10-06

Similar Documents

Publication Publication Date Title
MA39145B1 (fr) Dérivés de pipérazine ayant une activité multimode contre la douleur
MA41179A (fr) Composés inhibiteurs de parg
MA35869B1 (fr) Composés imidazopyrrolidinone
MA39219A1 (fr) Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
EA201290209A1 (ru) Новые модуляторы бензопиран киназы
MA47356A1 (fr) Dérivés d&#39;isochromène utiles en tant qu&#39;inhibiteurs des phosphoinositide 3-kinases
MA38039A1 (fr) Composés de céphem substitués en position 2
MA38284B1 (fr) Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one
MA44948A1 (fr) Inhibiteurs de bace 1
MA37946A1 (fr) Traitement de la polyarthrite rhumatoïde
MA35816B1 (fr) Dérivés d&#39;aniline, leur préparation et leur application thérapeutique
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
EA201590066A1 (ru) Дифторгексагидроциклопентаоксазинилы и дифторгексагидробензоксазинилы в качестве ингибиторов бета-секретазы 1
NZ744982A (en) Therapeutic compounds
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
MA43250B1 (fr) Composés d&#39;oxadiazaspiro pour le traitement de l&#39;abus et la dépendance aux drogues
MX2016006603A (es) Compuestos piperidinicos con actividad multimodal contra el dolor.
MA20150350A1 (fr) Dérivés isoxazolidine
MA35064B1 (fr) Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l&#39;arythmie
MA43158B1 (fr) Composés oxa-diazadispiro possédant une activité contre la douleur
WO2016187620A3 (fr) Composés anti-cancereux
FR3074421B1 (fr) Extrait d&#39;helichrysum gymnocephalum pour le traitement et/ou la prevention des dermatoses inflammatoires
MA38523A1 (fr) Composés triazoliques tricycliques utilisés en tant que ligands des récepteurs sigma
MA39101A1 (fr) Agonistes a1 de l&#39;adénosine utilisés comme médicaments contre les maladies des reins